{"publication_id":"81e7fb2b-c79b-471e-af0e-954eb243b39b","content_hash":"sha256:702acfd75ccd519df380a27fad6fa20644ad6ae740a570730efb81b97b4f291f","nodes":[{"id":"81e7fb2b-c79b-471e-af0e-954eb243b39b","type":"publication","title":"Bounded SGLT2 inhibitors signal: cited direct receipts are heterogeneous"},{"id":"claim_1","type":"claim","text":"The cited direct receipts support a heterogeneous working map, not one uniform effect estimate across the bundle."},{"id":"claim_2","type":"claim","text":"Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication."},{"id":"claim_3","type":"claim","text":"The surprise is the bounded heterogeneity: the cited direct receipts do not support one uniform effect estimate, so the useful alpha is the specific receipt map and its unresolved spread."},{"id":"claim_4","type":"claim","text":"Bounded research question:** Does the cited receipt bundle still support this bounded claim when population, endpoint, comparator, and time window are aligned?"},{"id":"claim_5","type":"claim","text":"`fact_id=95208` (`A_core`) — relative risk reductions in cardiovascular mortality (38%) doi=10.2174/1573399812666160613113556"},{"id":"claim_6","type":"claim","text":"`fact_id=160907` (`A_core`) — SGLT2I use was associated with lower risks of cardiovascular (HR:0.64, 95% CI: [0.49-0.85], P = 0.0017) mortality doi=10.3389/fcvm.2021.747620"},{"id":"claim_7","type":"claim","text":"`fact_id=75215` (`A_core`) — lower glycated hemoglobin (HbA1c) by 0.6-0.8% (6-8 mmol/mol) without increasing the risk of hypoglycemia Source: SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?"},{"id":"source_1","type":"source","study":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus","year":2016,"doi":"10.1161/circulationaha.116.021887","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_2","type":"source","study":"Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials","year":2016,"doi":"10.2174/1573399812666160613113556","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_3","type":"source","study":"Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors","year":2018,"doi":"10.1186/s12933-018-0745-5","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_4","type":"source","study":"Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis","year":2021,"doi":"10.3389/fcvm.2021.747620","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_5","type":"source","study":"Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review","year":2023,"doi":"10.1161/jaha.123.030578","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"}],"edges":[{"from":"81e7fb2b-c79b-471e-af0e-954eb243b39b","to":"claim_1","type":"contains_claim"},{"from":"81e7fb2b-c79b-471e-af0e-954eb243b39b","to":"claim_2","type":"contains_claim"},{"from":"81e7fb2b-c79b-471e-af0e-954eb243b39b","to":"claim_3","type":"contains_claim"},{"from":"81e7fb2b-c79b-471e-af0e-954eb243b39b","to":"claim_4","type":"contains_claim"},{"from":"81e7fb2b-c79b-471e-af0e-954eb243b39b","to":"claim_5","type":"contains_claim"},{"from":"81e7fb2b-c79b-471e-af0e-954eb243b39b","to":"claim_6","type":"contains_claim"},{"from":"81e7fb2b-c79b-471e-af0e-954eb243b39b","to":"claim_7","type":"contains_claim"}],"screening":{"identified":5,"screened":5,"excluded":0,"included":5,"included_or_retained":5,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"5 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]}}